Biogen: ADUHELM Continues To Reduce Underlying Pathologies O

WESTON (dpa-AFX) - Biogen Inc. (BIIB) said new data showed that after nearly two and a half years of treatment (128 weeks) with ADUHELM injection 100 mg/mL for intravenous use, patients in the

Related Keywords

Samantha Budd Haeberlein , Head Of Neurodegeneration Development At Biogen , Biogen Inc , Neurodegeneration Development , Biogen , Aduhelm , Ontinues , Educe , Underlying , Pathologies , Lzheimer , Beyond , Tears ,